yeh.jpg Ann E. Yeh
Columnista Experta de SIIC


Co-Director, Pediatric MS Center of the Jacobs Neurological Institute; Assistant Professor of Neurology, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, EE.UU.
NUEVAS TERAPIAS EN LA ESCLEROSIS MULTIPLE
Columnista Experta de SIIC Ann E. Yeh en colaboración con Weinstock-Guttman Bianca, MD, Buffalo, EE.UU.


Fecha de aprobación: 7 de febrero, 2007
Primera edición en siicsalud: 21 de agosto, 2007
Sección Artículos originales, subsección Expertos de Iberoamérica,
página /des/expertocompleto.php/87645  
Especialidad principal: Especialidad principalNeurología

Especialidades relacionadas:
Bioética,Farmacología,Medicina Farmacéutica,Medicina Interna,

  • Santos R, Weinstock-Guttman B, Tamano-Blanco M, Badgett D, Zivadinov R, Justinger T, Munschauer F, Ramanathan M. Dynamics of interferon-ß modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon- ß neutralizing antibodies., Journal of Neuroimmunology 176:125-133, 2006

  • Chadha K, Weinstock-Guttman B, Zivadinov R, Bhasi K, Muhitch J, Feichter J, Tamano-Blanco M, Abdelrahman N, Ambrus J Sr, Munschauer F, Ramanathan M. Interferon inhibitory activity in patients with multiple sclerosis., Archives of Neurology 63(63):1579-1584, 2006

  • Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, Bakshi R. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)., Archives of Neurology 63:957-963, 2006

  • Rudick RA, Stuart WH, Calabresi PA, , Confavreux C, Galetta SL, Hartung HP, Radue EW, Lublin FD, Weinstock-Guttman B, et al, for the SENTINEL Investigators. A randomized placebo-controlled trial of natalizumab in combination with interferon beta-1a for relapsing multiple sclerosis., New England Journal of Medicine 354(354):911-923, 2006

  • Benedict RH.B, Bruce JM, Dwyer MG, Abdelrahman N, Hussein S, Weinstock-Guttman B, Garg N, Munschauer F, Zivadinov R. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis., Archives of Neurology 63(63):1301-1306, 2006

  • Sanfilipo MP, Benedict RHB, Weinstock-Guttman B, Rohit Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis., Neurology 66:685-692, 2006

  • Weinstock-Guttman B, Hong J, Santos R, Tamaño-Blanco M, Badgett D, Patrick K, Baier M, Feichter J, Gallagher E, Garg N, Ramanathan M. Interferon-b modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients., Multiple Sclerosis 12(12):541-550, 2006

  • Brass SD , Benedict RHB, Weinstock-Guttman B, Munschauer F, Bakshi R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis., Multiple Sclerosis 12(12):437-444, 2006

  • Rudick RA, Cutter GR, Baier M, Weinstock-Guttman B, Mass MK, Fisher E, Miller DM, Sandrock AW Estimating long-term effects of disease modifying drug therapy in multiple sclerosis patients., Multiple Sclerosis 11(11):626-634, 2005

  • Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, Venkatraman J, Meksawan K, Deinehert S, Pendergast D, Awad A, Ramanathan M, Munschauer F, and Rudick R Low fat dietary intervention with ?-3 fatty acid supplementation in multiple sclerosis patients., Prostaglandins, Leukotrienes & Essential Fatty Acids. 73:397-404, 2005


  • Ann E. Yeh Los suscriptores, miembros de SIIC y socios del Círculo de Lectores pueden solicitar información adicional. Para enviarla, SIIC solicitará aprobación del autor.

    Dirección profesional:

    100 High Street, Suite E-2 - NY 14203, Buffalo, EE.UU.

    ua40317